Search results
Showing 31 to 45 of 99 results for pulmonary hypertension
This quality standard covers diagnosing and managing hypertension (high blood pressure) and pre-eclampsia during pregnancy, labour and birth. It also covers advice for women with hypertension who may become pregnant and postnatal care for women who have had hypertension or pre-eclampsia. It describes high-quality care in priority areas for improvement.
View quality statements for QS35Show all sections
Sections for QS35
- Quality statements
- Quality statement 1: Pre-pregnancy advice for women with treated hypertension
- Quality statement 2: Antenatal assessment of pre-eclampsia risk
- Quality statement 3: Antenatal blood pressure targets
- Quality statement 4: Assessing women with severe hypertension in pregnancy
- Quality statement 5: Admission to hospital for women with pre-eclampsia
- Quality statement 6: Timing of birth for women with pre-eclampsia
- Quality statement 7: Transfer of information about ongoing management
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.
Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (HTG376)
Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.
Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.
This evidence summary has been withdrawn following updated information in the summary of product characteristics on the off-label use of sildenafil (Revatio) in neonates with persistent pulmonary hypertension of the newborn.
Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over.
Chronic heart failure in adults: diagnosis and management (NG106)
This guideline covers diagnosing and managing chronic heart failure in people aged 18 and over. It aims to improve diagnosis and treatment to increase the length and quality of life for people with heart failure.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Further research should focus on the extended use of telemetric adjustable pulmonary artery banding for ventricular retraining and for...
This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.
Percutaneous balloon valvuloplasty for fetal critical aortic stenosis (HTG471)
Evidence-based recommendations on percutaneous balloon valvuloplasty for fetal critical aortic stenosis. This involves placing a catheter into the baby’s heart, while the baby is still in the womb. The aim is to help the heart develop properly.
View recommendations for HTG471Show all sections
Evidence-based recommendations on the early use of artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure.
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
Drugs for the treatment of pulmonary arterial hypertension [ID12]
Discontinued Reference number: GID-TAG382